A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-05-06
Adverse events
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 12); relationship: N
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 125); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-22 (study day 332); relationship: N
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-04 (study day 344); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-02 (study day 373); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-06-11 (study day 382); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-01-29 (study day 614); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-02-07 (study day 623); relationship: N
Data queries
No data queries.